This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?
by Zacks Equity Research
Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.
RMDPositive Net Change TFXPositive Net Change MEDPNegative Net Change HIMSNegative Net Change
medical medical-devices
QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test
by Zacks Equity Research
QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.
RMDPositive Net Change QGENNegative Net Change MEDPNegative Net Change HIMSNegative Net Change
medical medical-devices
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
DVANegative Net Change RMDPositive Net Change HOLXNegative Net Change MMSINegative Net Change
medical medical-devices
Cencora (COR) Stock Nosedives: Here's What Caused the Decline
by Zacks Equity Research
Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.
CAHNegative Net Change MCKNegative Net Change CORNo Net Change WBANegative Net Change
medical medical-devices
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
by Zacks Equity Research
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
ECLPositive Net Change BDXNegative Net Change UHSPositive Net Change DVANegative Net Change
medical medical-devices
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
ECLPositive Net Change DVANegative Net Change LMATPositive Net Change GKOSPositive Net Change
medical medical-devices
Thermo Fisher's (TMO) New Launch Speeds Up pDNA Purification
by Zacks Equity Research
Thermo Fisher (TMO) introduces the Thermo Scientific KingFisher PlasmidPro, the fully automated maxi-scale pDNA purification system.
TMOPositive Net Change RMDPositive Net Change MEDPNegative Net Change HIMSNegative Net Change
medical medical-devices
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.
SYKNegative Net Change DVANegative Net Change RMDPositive Net Change HOLXNegative Net Change
medical medical-devices
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CNMDPositive Net Change DVANegative Net Change RMDPositive Net Change HOLXNegative Net Change
medical medical-devices
Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
ECLPositive Net Change ISRGNegative Net Change DVANegative Net Change LMATPositive Net Change
medical medical-devices
Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices
by Zacks Equity Research
Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.
ECLPositive Net Change UHSPositive Net Change DVANegative Net Change EKSONo Net Change
medical medical-devices
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
UHSPositive Net Change DVANegative Net Change HQYNegative Net Change ELVNegative Net Change
medical medical-devices
Boston Scientific (BSX) DBS Programming Software Gets CE Mark
by Zacks Equity Research
Boston Scientific (BSX) secures CE Mark for the DBS image-guided programming software, Vercise Neural Navigator 5.
BSXNegative Net Change RMDPositive Net Change MEDPNegative Net Change HIMSNegative Net Change
medical medical-devices
Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now?
by Zacks Equity Research
Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues pose concerns.
DGXPositive Net Change RMDPositive Net Change MEDPNegative Net Change HIMSNegative Net Change
medical medical-devices
Here's Why You Should Retain Inari Medical (NARI) for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
DVANegative Net Change RMDPositive Net Change HOLXNegative Net Change NARIPositive Net Change
medical medical-devices
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
DVANegative Net Change RMDPositive Net Change HOLXNegative Net Change CORNo Net Change
medical medical-devices
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
by Zacks Equity Research
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
UHSPositive Net Change DVANegative Net Change AXGNPositive Net Change ELVNegative Net Change
medical medical-devices
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock
ECLPositive Net Change UHSPositive Net Change DVANegative Net Change ELVNegative Net Change
medical medical-devices
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
DVANegative Net Change XRAYPositive Net Change HOLXNegative Net Change HAEPositive Net Change
medical medical-devices
GE HealthCare's (GEHC) New Tie-Up to Boost CVD Workflow
by Zacks Equity Research
GE HealthCare's (GEHC) latest collaboration is likely to enable clinicians to perform complex cardiology interventions with a high level of precision and improved image quality.
ECLPositive Net Change DVANegative Net Change LMATPositive Net Change GEHCPositive Net Change
medical medical-devices
Illumina (ILMN) Rises on Conclusion of GRAIL Divestment
by Zacks Equity Research
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.
ILMNNegative Net Change RMDPositive Net Change MEDPNegative Net Change HIMSNegative Net Change
gene-therapy genomics medical medical-devices
Are Options Traders Betting on a Big Move in Alcon (ALC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alcon (ALC) stock based on the movements in the options market lately.
ALCNegative Net Change
medical medical-devices
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
GHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Omega Healthcare Investors (OHI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
OHINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Chewy (CHWY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CHWYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines